Eissele R, Goke R, Willemer S, Harthus HP, Vermeer H, Arnold R, and Goke B
General guidelines and dosing for patients with T2D: Initiate pramlintide at the 60 mcg dose taken immediately prior to major meals Titrate pramlintide to 120 mcg dose after 3 or more days with no clinically significant nausea Optimize insulin to achieve glycemic targets once the maintenance dose of pramlintide is reached and blood glucose concentrations are stable Practical Tips for Patients On Pramlintide Start With a Low Dose and Titrate Slowly Pramlintide can cause nausea, anorexia and vomiting, especially in T1D where a more gradual titration is required
The most robust clinical evidence to date concerns the improvement of muscular and metabolic parameters (strength, endurance, insulin sensitivity) and the modulation of chronic inflammation. A 2024 randomised trial comparing NAD IV with NR IV in healthy adults showed that both modalities increase the available NAD pool, with a favourable safety profile
At TrimRx, patient safety is our top priority
